title: Evolution of biologics screening technologies.
abstract: Screening for biologics, in particular antibody drugs, has evolved significantly over the last 20 years. Initially, the screening processes and technologies from many years experience with small molecules were adopted and modified to suit the needs of biologics discovery. Since then, antibody drug discovery has matured significantly and is today investing earlier in new technologies that commercial suppliers are now developing specifically to meet the growing needs of large molecule screening. Here, we review the evolution of screening and automation technologies employed in antibody discovery and highlight the benefits that these changes have brought.
authors.affiliation: MedImmune Ltd, Milstein Building, Granta Park, Cambridge CB21 6GH, UK. CariukP@MedImmune.com.
authors.forename: Peter
authors.initials: P
authors.lastname: Cariuk
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Gardener
authors.forename: Tristan J
authors.initials: TJ
authors.lastname: Vaughan